A novel case of neonatal severe hyperparathyroidism successfully treated with a type II calcimimetic drug

We report a boy with hypercalcemia due to neonatal severe hyperparathyroidism (NSHPT) caused by a compound heterozygous mutation in the calcium sensing receptor (CaSR) managed successfully on a type II calcimimetic drug. The hypercalcemia was temporarily treated by hyperhydration, bisphosphonate and...

Descripción completa

Detalles Bibliográficos
Autores principales: Leunbach, T.L., Hansen, A.T., Madsen, M., Cipliene, R., Christensen, P.S., Schou, A.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972953/
https://www.ncbi.nlm.nih.gov/pubmed/33748353
http://dx.doi.org/10.1016/j.bonr.2021.100761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972953/
https://www.ncbi.nlm.nih.gov/pubmed/33748353
http://dx.doi.org/10.1016/j.bonr.2021.100761

Ejemplares similares